Deterioration of Glycemic Control during Octreotide LAR Treatment in an Acromegalic Japanese Patient with Type 2 Diabetes Mellitus

DOI Web Site PubMed 参考文献26件 オープンアクセス
  • KAHARA Toshio
    Department of Internal Medicine, Toyama Prefectural Central Hospital
  • UENO Keiko
    Department of Internal Medicine, Toyama Prefectural Central Hospital
  • TORITA Muneyoshi
    Department of Internal Medicine, Toyama Prefectural Central Hospital
  • USUDA Rika
    Department of Internal Medicine, Toyama Prefectural Central Hospital
  • ABE Takumi
    Department of Neurosurgery, Showa University School of Medicine

この論文をさがす

説明

We report a case showing deterioration of glycemic control during octreotide long-acting release (LAR) treatment in an acromegalic Japanese patient with type 2 diabetes mellitus. The patient did not show much improvement of insulin sensitivity (QUICKI; 0.33 before treatment, 0.35 during octreotide LAR treatment), and showed a significant reduction in early insulin secretion (insulinogenic index; 0.28 before treatment, 0.08 during octreotide LAR treatment) on 75 g oral glucose tolerance test (75gOGTT), despite decreases in GH and IGF-I levels during the course of octreotide LAR treatment. Postoperatively, both insulin sensitivity and early insulin secretion on 75gOGTT were improved (QUICKI 0.59, insulinogenic index 0.35). There are some reports that insulinogenic index is lower in most Japanese patients with type 2 diabetes mellitus and that early insulin secretions are significantly suppressed after administration of octreotide LAR. Although the influence of octreotide LAR on glucose metabolism varies among individuals, it is necessary to manage the deterioration of glucose tolerance during octreotide LAR treatment in acromegalic Japanese patients with decreased insulinogenic index.<br>

収録刊行物

  • Endocrine Journal

    Endocrine Journal 54 (2), 329-333, 2007

    一般社団法人 日本内分泌学会

参考文献 (26)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ